IGM Biosciences Inc. (IGMS) Misses Q4 EPS by 6c

IGM Biosciences Inc. (NASDAQ: IGMS) reported Q4 EPS of ($0.49), $0.06 worse than the analyst estimate of ($0.43).

“2019 was a transformational year for IGM. The many highlights of the year included our successful initial public offering and the initiation of our first-in-human trial for our lead product candidate, IGM-2323, a CD20 x CD3 bispecific IgM antibody, in patients with relapsed/refractory non-Hodgkin’s lymphoma (NHL),” said Fred Schwarzer, Chief Executive Officer of IGM Biosciences. “We expect continued progress in 2020, with the filing of an Investigational New Drug application (IND) with the Food and Drug Administration (FDA) for our second product candidate, IGM-8444 and the presentation of initial data from our clinical trial of IGM-2323. With thanks to the IGM team, we believe we are well positioned to remain the global leader in the research and development of engineered therapeutic IgM antibodies.”

For earnings history and earnings-related data on IGM Biosciences Inc. (IGMS) click here.

You May Also Be Interested In

• AbbVie updates 2026 EPS guidance after $291M IPR&D charge
• LG Energy 2q Oper Profit 113.3b Won, Est. 210.66b Won - Bloomberg
• RxSight cuts 2026 sales outlook, citing competitive headwinds